Breaking News

Financial Results: Patheon 4Q12

December 17, 2012

CMO revenues up 18% in the quarter

Patheon

4Q Revenues: $210.0 million (flat) 

4Q Loss: $23.1 million (loss of $9.9 million in 4Q11)

YTD Revenues: $749.1 million (+7%)

YTD Loss: $106.7 million (loss of $16.4 million YTD11)

Comments: Commercial manufacturing revenues in the quarter were $172.7 million, up 18%, and for the year were $610.7 million, up 7%. Pharmaceutical Development Services revenues in the quarter were $37.5 million, up 7%, and for the year were $138.4 million, up 9%. The loss before discontinued operations was $106.4 million YTD compared to a loss of $15.8 million last year, primarily due to the asset impairment charge of $57.9 million related to closing the Swindon, UK facility.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks